ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Jubilant Pharmova received an [ICRA]AA+ (Stable) rating from ICRA for its proposed non-convertible debentures. This confirms the credit assessment for the upcoming debt instrument.
Jubilant Pharmova board approved NCD issuance up to ₹800 crore on private placement basis. Postal ballot also sought for NCD authorization up to ₹2,500 crore.
Jubilant Pharmova's Radiopharma business will invest CAD 94.5 million (approx. ₹633 Crore) to expand production capacity at its Kirkland facility, aiming to double RUBY-FILL® production.
Jubilant Pharmova Ltd has scheduled a board meeting for October 12, 2026, to consider raising funds via Non-Convertible Debentures and other permissible securities.
The Company issued a specimen letter to shareholders regarding withholding of FY 2025-26 final dividend due to incomplete KYC documents, as mandated by SEBI.
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Limited received a GST show cause notice proposing a demand of ₹87.31 Crore. The demand includes tax, interest, and penalties for FY 2022-2023.
Jubilant Pharmova's subsidiary received a GST show-cause notice for Rs. 105.50 Crore. The company is contesting the demand involving GST and an equal penalty.
Jubilant Pharmova held its 48th Annual General Meeting on August 26, 2026, via video conferencing. Shareholders approved all agenda items, including the final dividend declaration.
Jubilant Pharmova received USFDA approval for commercial batch manufacturing on the new Line 3 at its Spokane, U.S.A. contract manufacturing facility.
Jubilant Pharmova shareholders approved the re-appointment of Mr. Priyavrat Bhartia as MD and Mr. Arjun Shanker Bhartia as Joint MD via postal ballot.
Jubilant Pharmova reported Q1 FY27 revenue of ₹2,229 Crore, reflecting 17% YoY growth. Net profit stood at ₹56 Crore amidst margin impacts.
Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.
Jubilant Pharmova Limited has issued a notice for its 48th Annual General Meeting, scheduled for August 26, 2026, including the annual report for FY 2025-26.
Jubilant Pharmova Limited has scheduled a Board Meeting on August 07, 2026, to consider and approve the standalone and consolidated financial results for the quarter ended June 30, 2026.
Jubilant Pharmova informed the stock exchanges regarding the communication sent to shareholders concerning the transfer of unclaimed shares and dividends to the IEPF Authority.
Jubilant Pharmova Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details the distribution of equity shares across various categories.
Jubilant Pharmova has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Joint Managing Director.
Jubilant Pharmova approved the grant of 2,07,003 Stock Options, RSUs, and PSUs. The exercise prices range from Re. 1 to Rs. 974.45 per share.
Jubilant Pharmova received a rectification order deleting a Rs. 22.10 crore tax demand for AY 2020-21. Separate appeals on other grounds remain pending before ITAT.
Jubilant Pharmova received a tax rectification order disallowing Rs.53.37 Crore in brought forward losses. The company intends to appeal the decision.
Jubilant Pharmova's subsidiary received a tax rectification order reducing adjustments to ₹42.41 Crore. This provides a tax relief of ₹65.48 Crore.
Jubilant Pharmova received a USFDA Warning Letter for its Montreal facility following an inspection. Operations continue under enhanced oversight while the company initiates corrective remediation actions.
Jubilant Pharmova Limited filed its Annual Secretarial Compliance Report for FY 2025-26. The report confirms overall regulatory compliance with no material deviations or fines noted.